New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

[News]

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

More... (http://www.news-medical.net/news/20100729/New-Zealand-MEDSAFE-approves-ABRAXANE-for-metastatic-breast-cancer.aspx)